EFCCA is involved in an exciting new Horizon Europe project called FIBROTARGET. This project aims to validate novel immunotherapeutic targets against fibrosis in inflammatory bowel disease in order to obtain patients and regulatory approval for implementation of these novel noninvasive imaging modalities as diagnostic and prognostic tools for fibrotic IBD.
November, 2022
The study developed a core outcome set for real-world studies in adult patients with inflammatory bowel disease (IBD). Other indicators include, for example, clinical, endoscopic, and biomarker remission, fatigue, and urgency to go to the toilet.
READ MORE
IBD HAS NO AGE is an EFCCA campaign started in 2022 in order to raise awareness of how Inflammatory Bowel Disease (IBD) is impacting on the life of people aged 60 years and over. This year, for World IBD Day 2023 (19 May), we will launch a survey on people with IBD aged 60 years and over to investigate more on this topic with questions related to both quality of care and quality of life.
The METHYLOMIC project will build on multiple previous cohort studies that confirmed epigenetic biomarkers (specifically DNA methylation) as the most stringent predictor of response to biological therapy, zooming in on CD. DNA methylation profiles in peripheral blood as biomarkers of response/deep remission for three approved biologicals in CD have been specifically discovered and validated.
The GlycanTrigger project proposes a thorough and innovative approach to understand better the health-to-chronic inflammation transition occurring in patients with CD that will be translated into improved disease prediction and prevention.
The GENEGUT project will transform the treatment of ileal CD by developing a first-in-class oral RNA-based therapy, tackling inflammation locally in the intestinal tissue, while avoiding systemic side effects.
EFCCA is involved in an exciting EU Research Project under the Innovative Medicines Initiative (IMI 2) (Horizon 2020).
The ImmUniverse project main goal is the improved diagnostic and therapeutic options for patients living with ulcerative colitis and atopic dermatitis. New insights into disease severity and progression will enable personalised therapy for each individual patient.
EFCCA is involved in this exciting project that will identify digital endpoints that provide reliable, objective and sensitive evaluation of activities of daily living and Health-related quality of life (HRQoL) in ImmuneMediated Inflammatory Diseases such as IBD as well as other such as Rheumatoid Arthritis and Lupus and which will ultimately have a positive impact on the quality of life of these patients.
Background
October, 2022
There is a high variability of out-of-packet patient costs of inflammatory bowel diseases (IBDs), but the issue is not widely recognised. Therefore, the study compared patient costs of IBDs between 12 European countries.